Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma
Arcellx (ACLX) closed down ~17% Monday after privately held Kelonia Therapeutics released early-stage results from a small...
Tag: JNJ
Key deals this week: Kenvue, Warner Bros. Discovery, Adobe, Workday and more
Here's a list of key deals reported across sectors this week: Kenvue (KVUE) rose 3% amid some speculation about a possible...
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis
The U.S. FDA on Thursday granted traditional approval for Darzalex Faspro, an injectable version of the multiple myeloma...
Johnson & Johnson falls after six-sessions of gain
Johnson & Johnson (JNJ) slipped 0.18% to $199.22 in afternoon trade on Tuesday, ending six-sessions of gain. Despite...
Zymeworks shifts to a royalty-driven business model
Zymeworks (ZYME) on Tuesday announced plans to focus on a royalty-driven growth model backed by its internal R&D engine...
J&J reports positive data from late-stage Tremfya study
Johnson & Johnson (JNJ) reported positive data from a late stage study of Tremfya for the treatment of active psoriatic...
Johnson & Johnson to buy Halda Therapeutics for $3.05B
Johnson & Johnson (JNJ) has announced its plan to purchase Halda Therapeutics, a firm focused on developing oral...
Bristol Myers falls after late-stage trial setback for J&J-partnered blood thinner
Shares of Bristol Myers Squibb (BMY) fell ~5% in the premarket on Friday after the company said that a Phase 3 trial for...
Johnson & Johnson gains smoldering multiple myeloma indication for Darzalex Faspro
The U.S. FDA has approved Johnson & Johnson's (JNJ) Darzalex Faspro (daratumumab and hyaluronidase) for a new...
J&J wins FDA label expansion for Caplyta against depression
Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration has further expanded the...